Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Actinic keratosis modelling in mice: A translational study.

Pillon A, Gomes B, Vandenberghe I, Cartron V, Cèbe P, Blanchet JC, Sibaud V, Guilbaud N, Audoly L, Lamant L, Kruczynski A.

PLoS One. 2017 Jun 29;12(6):e0179991. doi: 10.1371/journal.pone.0179991. eCollection 2017.

2.

Discovery bioanalysis and in vivo pharmacology as an integrated process: a case study in oncology drug discovery.

Grondin A, Pillon A, Vandenberghe I, Guilbaud N, Kruczynski A, Gomes B.

Bioanalysis. 2016 Jul;8(14):1481-98. doi: 10.4155/bio-2016-0062. Epub 2016 Jun 17.

PMID:
27314564
3.

F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

Thibault B, Clement E, Zorza G, Meignan S, Delord JP, Couderc B, Bailly C, Narducci F, Vandenberghe I, Kruczynski A, Guilbaud N, Ferré P, Annereau JP.

Cancer Lett. 2016 Jan 1;370(1):10-8. doi: 10.1016/j.canlet.2015.09.006. Epub 2015 Sep 25.

PMID:
26404751
4.

Stathmin potentiates vinflunine and inhibits Paclitaxel activity.

Malesinski S, Tsvetkov PO, Kruczynski A, Peyrot V, Devred F.

PLoS One. 2015 Jun 1;10(6):e0128704. doi: 10.1371/journal.pone.0128704. eCollection 2015.

5.

Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.

Créancier L, Vandenberghe I, Gomes B, Dejean C, Blanchet JC, Meilleroux J, Guimbaud R, Selves J, Kruczynski A.

Cancer Lett. 2015 Aug 28;365(1):107-11. doi: 10.1016/j.canlet.2015.05.013. Epub 2015 May 19.

PMID:
26001971
6.

Synthesis and biological evaluation of (-)-6-O-desmethylcryptopleurine and analogs.

Liéby-Muller F, Marion F, Schmitt P, Annereau JP, Kruczynski A, Guilbaud N, Bailly C.

Bioorg Med Chem Lett. 2015 Jan 15;25(2):184-7. doi: 10.1016/j.bmcl.2014.11.086. Epub 2014 Dec 6.

PMID:
25499434
7.

End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo.

Berges R, Baeza-Kallee N, Tabouret E, Chinot O, Petit M, Kruczynski A, Figarella-Branger D, Honore S, Braguer D.

Oncotarget. 2014 Dec 30;5(24):12769-87.

8.

Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines.

Leblond P, Boulet E, Bal-Mahieu C, Pillon A, Kruczynski A, Guilbaud N, Bailly C, Sarrazin T, Lartigau E, Lansiaux A, Meignan S.

Invest New Drugs. 2014 Oct;32(5):883-92. doi: 10.1007/s10637-014-0132-3. Epub 2014 Jul 11.

PMID:
25008900
9.

Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status.

Rovini A, Gauthier G, Bergès R, Kruczynski A, Braguer D, Honoré S.

PLoS One. 2013 Jun 4;8(6):e65694. doi: 10.1371/journal.pone.0065694. Print 2013.

10.

F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.

Kruczynski A, Pillon A, Créancier L, Vandenberghe I, Gomes B, Brel V, Fournier E, Annereau JP, Currie E, Guminski Y, Bonnet D, Bailly C, Guilbaud N.

Leukemia. 2013 Nov;27(11):2139-48. doi: 10.1038/leu.2013.108. Epub 2013 Apr 9.

PMID:
23568148
11.

Anaplastic lymphoma kinase as a therapeutic target.

Kruczynski A, Delsol G, Laurent C, Brousset P, Lamant L.

Expert Opin Ther Targets. 2012 Nov;16(11):1127-38. doi: 10.1517/14728222.2012.719498. Epub 2012 Sep 24. Review.

PMID:
22998583
12.

Optical imaging of disseminated leukemia models in mice with near-infrared probe conjugated to a monoclonal antibody.

Pesnel S, Pillon A, Créancier L, Lerondel S, Le Pape A, Recher C, Demur C, Guilbaud N, Kruczynski A.

PLoS One. 2012;7(1):e30690. doi: 10.1371/journal.pone.0030690. Epub 2012 Jan 27.

13.

Use of an image restoration process to improve spatial resolution in bioluminescence imaging.

Pesnel S, Akkoul S, Ledée R, Leconge R, Pillon A, Kruczynski A, Harba R, Lerondel S, Le Pape A.

Mol Imaging. 2011 Dec;10(6):446-52.

PMID:
22201535
14.

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

LaRochelle O, Bertoli S, Vergez F, Sarry JE, Mansat-De Mas V, Dobbelstein S, Dastugue N, Strzelecki AC, Cavelier C, Creancier L, Pillon A, Kruczynski A, Demur C, Sarry A, Huguet F, Huynh A, Récher C, Delabesse E.

Oncotarget. 2011 Nov;2(11):850-61.

15.

Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.

Brel V, Annereau JP, Vispé S, Kruczynski A, Bailly C, Guilbaud N.

Biochem Pharmacol. 2011 Dec 15;82(12):1843-52. doi: 10.1016/j.bcp.2011.08.028. Epub 2011 Sep 8.

PMID:
21924246
16.

99mTc-HYNIC-spermine for imaging polyamine transport system-positive tumours: preclinical evaluation.

Pesnel S, Guminski Y, Pillon A, Lerondel S, Imbert T, Guilbaud N, Kruczynski A, Bailly C, Le Pape A.

Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1832-41. doi: 10.1007/s00259-011-1857-2. Epub 2011 Jun 10.

PMID:
21660624
17.

MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.

Desjobert C, Renalier MH, Bergalet J, Dejean E, Joseph N, Kruczynski A, Soulier J, Espinos E, Meggetto F, Cavaillé J, Delsol G, Lamant L.

Blood. 2011 Jun 16;117(24):6627-37. doi: 10.1182/blood-2010-09-301994. Epub 2011 Apr 6.

18.

Quantitation in bioluminescence imaging by correction of tissue absorption for experimental oncology.

Pesnel S, Pillon A, Créancier L, Guilbaud N, Bailly C, Kruczynski A, Lerondel S, Le Pape A.

Mol Imaging Biol. 2011 Aug;13(4):646-52. doi: 10.1007/s11307-010-0387-9.

PMID:
20686859
19.

A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway?

Renner AG, Créancier L, Dos Santos C, Fialin C, Recher C, Bailly C, Kruczynski A, Payrastre B, Manenti S.

Cell Cycle. 2010 May;9(9):1690-6. Epub 2010 May 25.

PMID:
20404504
20.

Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.

Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F.

Blood. 2010 May 20;115(20):4061-70. doi: 10.1182/blood-2008-06-163386. Epub 2010 Mar 11.

21.

Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system.

Kruczynski A, Vandenberghe I, Pillon A, Pesnel S, Goetsch L, Barret JM, Guminski Y, Le Pape A, Imbert T, Bailly C, Guilbaud N.

Invest New Drugs. 2011 Feb;29(1):9-21. doi: 10.1007/s10637-009-9328-3. Epub 2009 Sep 24.

PMID:
19777159
22.

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.

Renner AG, Dos Santos C, Recher C, Bailly C, Créancier L, Kruczynski A, Payrastre B, Manenti S.

Blood. 2009 Jul 16;114(3):659-62. doi: 10.1182/blood-2008-12-195867. Epub 2009 May 20.

23.

Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.

Kruczynski A, Mayer P, Marchand A, Vispé S, Fournier E, Annereau JP, Brel V, Barret JM, Delsol G, Imbert T, Fahy J, Bailly C.

Anticancer Drugs. 2009 Jun;20(5):364-72. doi: 10.1097/CAD.0b013e32832a2ed9.

PMID:
19322071
24.

F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.

Barret JM, Kruczynski A, Vispé S, Annereau JP, Brel V, Guminski Y, Delcros JG, Lansiaux A, Guilbaud N, Imbert T, Bailly C.

Cancer Res. 2008 Dec 1;68(23):9845-53. doi: 10.1158/0008-5472.CAN-08-2748.

25.

Antitumor activity of vinflunine: effector pathways and potential for synergies.

Braguer D, Barret JM, McDaid H, Kruczynski A.

Semin Oncol. 2008 Jun;35(3 Suppl 3):S13-21. doi: 10.1053/j.seminoncol.2008.01.011. Review.

PMID:
18538174
26.

Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites.

Honoré S, Pagano A, Gauthier G, Bourgarel-Rey V, Verdier-Pinard P, Civiletti K, Kruczynski A, Braguer D.

Mol Cancer Ther. 2008 Jul;7(7):2080-9. doi: 10.1158/1535-7163.MCT-08-0156.

27.

Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis.

Vandenberghe I, Créancier L, Vispé S, Annereau JP, Barret JM, Pouny I, Samson A, Aussagues Y, Massiot G, Ausseil F, Bailly C, Kruczynski A.

Biochem Pharmacol. 2008 Aug 15;76(4):453-62. doi: 10.1016/j.bcp.2008.05.031. Epub 2008 Jun 4.

PMID:
18577376
28.

Synthesis and biological evaluation of bengacarboline derivatives.

Pouilhès A, Kouklovsky C, Langlois Y, Baltaze JP, Vispé S, Annereau JP, Barret JM, Kruczynski A, Bailly C.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1212-6. Epub 2007 Dec 4.

PMID:
18083028
29.

Murine leukemia P388 vinorelbine-resistant cell lines are sensitive to vinflunine.

Aggarwal A, Kruczynski A, Frankfurter A, Correia JJ, Lobert S.

Invest New Drugs. 2008 Aug;26(4):319-30. Epub 2007 Dec 11.

PMID:
18071633
30.

Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.

Vispé S, Vandenberghe I, Robin M, Annereau JP, Créancier L, Pique V, Galy JP, Kruczynski A, Barret JM, Bailly C.

Biochem Pharmacol. 2007 Jun 15;73(12):1863-72. Epub 2007 Mar 3.

PMID:
17391647
31.

High-throughput bioluminescence screening of ubiquitin-proteasome pathway inhibitors from chemical and natural sources.

Ausseil F, Samson A, Aussagues Y, Vandenberghe I, Creancier L, Pouny I, Kruczynski A, Massiot G, Bailly C.

J Biomol Screen. 2007 Feb;12(1):106-16. Epub 2006 Dec 14.

PMID:
17175525
32.

Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.

Estève MA, Carré M, Bourgarel-Rey V, Kruczynski A, Raspaglio G, Ferlini C, Braguer D.

Mol Cancer Ther. 2006 Nov;5(11):2824-33.

33.

Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.

Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT, Taraboletti G.

Eur J Cancer. 2006 Nov;42(16):2821-32. Epub 2006 Sep 14.

PMID:
16973349
34.

Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.

Pourroy B, Honoré S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, Braguer D.

Cancer Res. 2006 Mar 15;66(6):3256-63.

35.

Cytotoxic arylnaphthalene lignans from a Vietnamese acanthaceae, Justicia patentiflora.

Susplugas S, Hung NV, Bignon J, Thoison O, Kruczynski A, Sévenet T, Guéritte F.

J Nat Prod. 2005 May;68(5):734-8.

PMID:
15921419
36.

Antitumor pharmacology -- quo vadis?

Bailly C, Barret JM, Kruczynski A.

Curr Med Chem Anticancer Agents. 2004 Sep;4(5):389-91. Review.

PMID:
15379689
37.

Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway.

Pourroy B, Carré M, Honoré S, Bourgarel-Rey V, Kruczynski A, Briand C, Braguer D.

Mol Pharmacol. 2004 Sep;66(3):580-91.

PMID:
15322250
38.
39.

Novel aspects of natural and modified vinca alkaloids.

Duflos A, Kruczynski A, Barret JM.

Curr Med Chem Anticancer Agents. 2002 Jan;2(1):55-70. Review.

PMID:
12678751
40.

Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II.

Etiévant C, Kruczynski A, Barret JM, Perrin D, Hill BT.

Biochem Pharmacol. 2003 Mar 1;65(5):755-63.

PMID:
12628489
41.
42.

Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.

Barret JM, Kruczynski A, Etiévant C, Hill BT.

Cancer Chemother Pharmacol. 2002 Jun;49(6):479-86. Epub 2002 Apr 6.

PMID:
12107553
43.

Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development.

Kruczynski A, Etiévant C, Perrin D, Chansard N, Duflos A, Hill BT.

Br J Cancer. 2002 Jan 7;86(1):143-50.

44.

Classic in vivo cancer models: three examples of mouse models used in experimental therapeutics.

Kruczynski A, Hill BT.

Curr Protoc Pharmacol. 2002 Feb;Chapter 5:Unit5.24. doi: 10.1002/0471141755.ph0524s15.

PMID:
21959766
45.

Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties.

Kruczynski A, Hill BT.

Crit Rev Oncol Hematol. 2001 Nov;40(2):159-73. Review.

PMID:
11682323
46.
47.

Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II.

Barret JM, Montaudon D, Etiévant C, Perrin D, Kruczynski A, Robert J, Hill BT.

Anticancer Res. 2000 Nov-Dec;20(6B):4557-62.

PMID:
11205304
49.

Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases.

Kruczynski A, Etiévant C, Perrin D, Imbert T, Colpaert F, Hill BT.

Br J Cancer. 2000 Dec;83(11):1516-24.

Supplemental Content

Loading ...
Support Center